Evaluation of the precision and accuracy in the classification of breast histopathology images using the MobileNetV3 model.

Accurate surgical pathological assessment of breast biopsies is essential to the proper management of breast lesions. Identifying histological features, such as nuclear pleomorphism, increased mitotic activity, cellular atypia, patterns of architectural disruption, as well as invasion through basement membranes into surrounding stroma and normal structures, including invasion of vascular and lymphatic spaces, help to classify lesions as malignant. This visual assessment is repeated on numerous slides taken at various sections through the resected tumor, each at different magnifications. Computer vision models have been proposed to assist human pathologists in classification tasks such as these. Using MobileNetV3, a convolutional architecture designed to achieve high accuracy with a compact parameter footprint, we attempted to classify breast cancer images in the BreakHis_v1 breast pathology dataset to determine the performance of this model out-of-the-box. Using transfer learning to take advantage of ImageNet embeddings without special feature extraction, we were able to correctly classify histopathology images broadly as benign or malignant with 0.98 precision, 0.97 recall, and an F1 score of 0.98. The ability to classify into histological subcategories was varied, with the greatest success being with classifying ductal carcinoma (accuracy 0.95), and the lowest success being with lobular carcinoma (accuracy 0.59). Multiclass ROC assessment of performance as a multiclass classifier yielded AUC values ≥0.97 in both benign and malignant subsets. In comparison with previous efforts, using older and larger convolutional network architectures with feature extraction pre-processing, our work highlights that modern, resource-efficient architectures can classify histopathological images with accuracy that at least matches that of previous efforts, without the need for labor-intensive feature extraction protocols. Suggestions to further refine the model are discussed.

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget's Disease.

Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We describe the favorable response of a 72-year-old man with extramammary Paget's disease, whose disease has been controlled with the CDK4/6 inhibitor, abemaciclib. The rationale behind the selection of this therapy is discussed.

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

PURPOSE: Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablation are used for hepatic metastatic neuroendocrine tumor (NET) therapy. Results from another minimally invasive therapy, radioembolization, remain unknown. The purpose of this multicenter open label phase II study was to assess the efficacy and safety of yttrium-90 (Y) radioembolization for treating hepatic metastatic NET using a primary outcome of tumor response and secondary outcomes of serologic toxicities and survival. MATERIAL/METHODS: In this multicenter study, all patients underwent lobar radioembolization using glass or resin Y radioembolic agents. Patients were assessed serologically and radiographically at 2 to 4 weeks and then at 1 to 3 month intervals after treatment. We 1) compared liver volumes, radiation doses, and serologic liver function tests (unpaired t test, P = 0.05) and 2) assessed tumor response, serologic toxicity, and median survival from first Y therapy. The clinicaltrials.gov identifier was NCT00532740. RESULTS: Forty-two patients underwent radioembolization using glass (mean age 58 +/- 12 years) or resin (mean age 61 +/- 11 years) microspheres. A statistically significant greater median radiation dose was delivered to each lobe using glass (right lobe 117 Gy; left lobe 108 Gy) than using resin (right 50.8 Gy; left 44.5 Gy) (P < 0.01). Using Response Criteria in Solid Tumors, 92% of glass and 94% of resin patients were classified as partial response or stable disease at 6 months after treatment. Six patients experienced grade 3/4 toxicities during the follow-up period. Median survival was 22 months (glass) and 28 months (resin) (P = 0.82). CONCLUSION: Y radioembolization of metastatic NET is a viable therapy with acceptable toxicity. Further investigation is warranted.

Management of femoral fracture in a patient with essential thrombocythemia treated with plateletpheresis and intramedullary rod fixation, followed by hydroxyurea: a case report.

We describe the management of a patient with a femoral fracture who had asymptomatic essential thrombocythemia. When the diagnosis of essential thrombocythemia was made, the patient was treated with plateletpheresis to reduce the platelet count before intramedullary rod fixation of his fracture. His postoperative management included the examination of his peripheral blood as well as bone marrow, which confirmed that the cause of his elevated platelet count was due to JAK2 V617F mutation that is treated by hydroxyurea and aspirin after being discharged from the hospital.

Neoadjuvant chemoradiotherapy for esophageal cancer using weekly Paclitaxel and Carboplatin plus infusional 5-Fluorouracil.

PURPOSE: To evaluate neoadjuvant therapy with weekly paclitaxel/carboplatin plus 5-fluorouracil (5-FU) with conformal radiotherapy in a phase II trial in resectable esophageal carcinoma. METHODS: Twenty-four patients with T2-4N0-1M0-1a esophageal carcinoma were treated with paclitaxel 45 mg/m(2) intravenously over 1 hour and carboplatin at an area under the concentration-time curve (AUC) of 2 intravenously over 30 minutes on days 1, 8, 15, 22, and 29. 5-Fluorouracil 225 mg/m(2) was delivered as a continuous infusion on days 1-33. Concurrent conformal radiation was delivered to a dose of 45 Gy. Responders underwent surgical resection within 8 weeks of completing chemoradiotherapy. Kaplan-Meier survival analysis and log-rank test of survival dependent on pathologic response were performed. RESULTS: Progressive disease was discovered at surgery in three patients. Of the remaining 21 patients, pathologic complete response (pCR) was demonstrated in 12 (pCR rate of 57%) and partial response (PR) occurred in 9, including 4 with near complete response. Median follow-up in all patients was 23 months. Overall survival among all 24 patients was 48% at 3 years, with a median of 31 months. Disease-free survival was 57% at 3 years, with a median of 38 months. Differences in survival time based on pCR vs. PR showed a trend favoring pCR for disease-free survival (P = .12) but not overall survival (P > .20). Grade 3/4 toxicities included esophagitis in 33% of patients, hypotension in 29%, stomatitis in 25%, neutropenia in 13%, and anemia in 8%. CONCLUSION: This study demonstrates the activity of neoadjuvant paclitaxel, carboplatin, 5-FU, and conformal radiotherapy in the treatment of localized esophageal cancer. Evaluation with a larger number of patients and longer follow-up will be required to definitively assess the long-term efficacy of this regimen.